Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors

Title
Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors
Authors
Keywords
ATI-1123, Docetaxel, Safety, Tolerability, Pharmacokinetics
Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 74, Issue 6, Pages 1241-1250
Publisher
Springer Nature
Online
2014-10-10
DOI
10.1007/s00280-014-2602-x

Ask authors/readers for more resources

Reprint

Contact the author

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started